In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
In the wake of big patent decision, it’s business as usual for CRISPR therapy developers"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
NEW YORK — Earlier this month, the U.S. Patent and Trademark Office ruled that CRISPR patents key to developing human therapies belong to the Broad Institute of MIT and Harvard, ending the
latest chapter in a bitter seven-year battle between the Broad and the home institutions of Jennifer Doudna and Emmanuelle Charpentier — the two scientists who won the Nobel Prize for
creating the revolutionary gene-editing technology.
But for all the acrimony exchanged and millions of dollars of legal fees spent by the academic institutions where CRISPR was first invented, the companies that are actually turning the
technology into medicines are plowing through the fallout of the decision with little more than a collective shrug.
“I think it’s really a topic for people interested in IP law,” Lawrence Klein, the chief operating officer of CRISPR Therapeutics said Thursday during the 2022 STAT Breakthrough Science
Summit in New York City.
Trending News
Dems know it's warming but not how to fix itClimate change is the first big fight for congressional Democrats as they prepare to take control of the House next year...
Sky confirms voice-controlled 'hands-free tv'* SKY IS DEVELOPING TECHNOLOGY THAT MAKES ITS SET-TOP BOXES VOICE-CONTROLLED * VIEWERS WILL BE ABLE TO SWITCH CHANNELS A...
Genome-wide association study identifies 1p36. 22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis b virus carriersABSTRACT To identify susceptibility variants for hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), we cond...
Software engineer (f/m/x) python | eu-startupsMagazino is a tech startup and robotics company based in Munich, Germany. Our team of hardware and software engineers i...
We Are Bellingcat by Eliot Higgins review – the reinvention of reporting for the internet age | Journalism books | The GuardianA protest in Moscow in support of Vladimir Putin critic Alexei Navalny, whose attackers were identified by Bellingcat. P...
Latests News
In the wake of big patent decision, it’s business as usual for CRISPR therapy developersNEW YORK — Earlier this month, the U.S. Patent and Trademark Office ruled that CRISPR patents key to developing human th...
Javascript support required...
Protein Degradation in Focus | Nature Chemical BiologyIn May 2024, ‘Protein Degradation in Focus’, a special symposium aimed at bringing together scientists in the targeted p...
CDC Alerts Over Potential Mpox ResurgenceAs CDC investigates a cluster of mpox cases in the Chicago area, the agency is asking clinicians and public health agenc...
Javascript support required...